A 38-year-old man from Mumbai undergoes total thyroidectomy for a 3 cm papillary thyroid carcinoma (PTC) with no extrathyroidal extension or lymph node involvement (Stage I). Histology confirms classical variant PTC. Postoperative TSH is 2.5 mIU/L. What is the most appropriate next step in management?

Explanation

## Risk Stratification in Papillary Thyroid Carcinoma This patient has **low-risk PTC** (Stage I: <4 cm, no extrathyroidal extension, no lymph node involvement, classical variant). Risk stratification determines the intensity of follow-up and need for radioactive iodine (RAI). ## Management by Risk Category | Feature | Low-Risk | Intermediate-Risk | High-Risk | |---------|----------|-------------------|----------| | **Tumor size** | <4 cm | Any | Any | | **Extrathyroidal extension** | Absent | Minimal | Gross | | **Lymph node involvement** | None | N1a or N1b | N1b with extranodal extension | | **Distant metastases** | Absent | Absent | Present | | **RAI ablation** | Not routinely needed | Consider | Recommended | | **TSH target** | 0.5–2 mIU/L | 0.1–0.5 mIU/L | <0.1 mIU/L | ## Key Point: **Low-risk PTC does NOT routinely require radioactive iodine ablation.** TSH suppression to 0.5–2 mIU/L (mild suppression) is appropriate, with surveillance by thyroglobulin and ultrasound. ## High-Yield: **ATA 2015 Guidelines:** RAI ablation is **not recommended** for low-risk PTC (Stage I, no high-risk features). Aggressive TSH suppression (<0.1 mIU/L) is reserved for high-risk disease and increases cardiovascular and bone morbidity without clear benefit in low-risk patients. ## Clinical Pearl: Thyroglobulin is an excellent tumor marker in PTC. Undetectable thyroglobulin on levothyroxine monotherapy with normal ultrasound is reassuring and indicates excellent prognosis in low-risk disease. Serial measurement guides follow-up intensity.